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Abstract The development of autoimmunity and/or autoim-
mune diseases is multifactorial. Vitamin D is one of the factors
that might play a role. We postulated that both the presence of
adjuvants and insufficient levels of vitamin D may result in the
development of autoimmunity in patients with autoimmune/
inflammatory syndrome induced by adjuvants (ASIA) in relation
to silicone implant incompatibility. We measured vitamin D
levels in 135 patients with ASIA in relation to silicone implant
incompatibility and related findings to the presence of autoanti-
bodies that are commonly used to diagnose systemic autoim-
mune diseases. Furthermore, we systematically reviewed the lit-
erature regarding vitamin D deficiency as a risk factor for the
development of autoantibodies. Vitamin D measurements were
available for analysis in 131 of 135 patientswithASIA in relation
to SIIS. Twenty-three patients (18%) tested positive for autoan-
tibodies, from which 18 patients (78%) had either a vitamin D
deficiency or insufficiency (median vitamin D level 60.5 mmol/
L), whereas five patients (22%) had sufficient vitamin D levels.
The risk to develop autoantibodies was significantly increased in
vitamin D deficient and/or insufficient patients [RR 3.14; 95%
CI, 1.24–7.95; p = 0.009]. Reviewed literature suggested an
association between vitamin D levels and the presence and/or
titer levels of autoantibodies in different autoimmune diseases.
From our current study and from our review of the literature, we
conclude that vitamin D deficiency is related to the presence of
autoantibodies. Whether vitamin D supplementation results in a
decrease of autoimmunity needs to be studied prospectively.
Keywords Autoantibodies . Autoimmune diseases . Vitamin
D . VitaminD deficiency . VitaminD supplementation
Introduction
Silicone breast implants may be associated with nonspecific
symptoms such as fatigue, myalgia, arthralgia, pyrexia, dry
mouth, dry eyes, and cognitive impairment [1–3]. Explantation
of the breast implants results in improvement of the symptoms in
50–80% of the patients [1, 4]. At present, it is still controversial
whether silicone-filled breast implants increase the risk of auto-
immunity [3, 5, 6]. Recently, however, it has been suggested that
an increased prevalence of autoimmune diseases such as rheu-
matoid arthritis and Sjögren’s syndrome exists in these patients
[6]. Moreover, immune deficiency may occur in these patients at
an increased frequency [3]. Finally, several autoantibodies have
been reported to occur in silicone breast implant patients at an
increased frequency [7–11]. Also, these findings are, however,
controversial [11, 12].
Vitamin D is known to be a crucial factor in the calcium
homeostasis. Vitamin D, however, is also essential for immunity.
Importantly, vitamin D deficiency may represent a global health
problem that has been underestimated for many years [13]. Over
the last decades, it has been shown that vitamin D deficiency is
associated with an increased risk for infectious diseases [14].
Moreover, a number of autoimmune diseases, including multiple
sclerosis, type I diabetes, inflammatory bowel disease, systemic
lupus erythematosus, and rheumatoid arthritis, are reported to be
associated with vitamin D deficiency [15–17].
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Several mechanisms by which vitamin D acts as a regulatory
agent for the innate as well as the adaptive immune system have
been described [18]. Firstly, cells of the immune system have
been shown to be direct targets of vitamin D metabolites.
Secondly, many immune cells contain enzymes of the cyto-
chrome P (CYP) family and are thus able to convert 25(OH)D
into calcitriol, the biologically active form of vitamin D [18, 19].
Since vitamin D is known to be a potent regulator of the
immune system [18] and vitamin D deficiency is hypothesized
to contribute to B cell hyperactivity [19], we postulate that vita-
min D deficiency is a risk factor for the development of autoan-
tibodies in patients with autoimmune/inflammatory syndrome
induced by adjuvants (ASIA) in relation to silicone implant in-
compatibility syndrome (SIIS) [3, 20]. To study this, we exam-
ined vitamin D levels in patients with ASIA in relation to SIIS
and related findings to the presence of autoantibodies.
Furthermore, we reviewed the effect of vitamin D deficiency as




One hundred thirty-five consecutive ASIA in relation to SIIS
patients were included in the current study. The patients were
prospectively evaluated between January 2014 and September
2015 by one of us (JWCT). A diagnosis of ASIA was made
based on criteria as previously described [2]. In short, patients
were diagnosed as suffering from ASIAwhen either two ma-
jor or one major and two minor criteria were present. Criteria
are summarized in Table 1.
Laboratory investigation
All patients underwent laboratory evaluations including mea-
surements of vitamin D, antinuclear antibodies (ANA), anti-
bodies to extractable nuclear antigens (ENA), anti-cardiolipin
antibodies (anti-CL), anti-β2 glycoprotein-1 antibodies, anti-
neutrophil cytoplasmic antibodies (ANCA), IgM rheumatoid
factor (RF), and anti-cyclic citrullinated peptide (anti-CCP)
antibodies [21–27]. If a positive ANAwas found, serum was
tested for anti-double-stranded DNA antibodies (anti-dsDNA)
[26], and if the ANCA test was positive, samples were addi-
tionally tested for PR3-ANCA and MPO-ANCA [25].
Vitamin D status was evaluated by measurement of serum
25(OH)D levels with a chemiluminescent immunoassay method
by Roche Cobas, Roche, Basel, Switzerland. Serum 25(OH)D
levels below 50 nmol/L (20 ng/mL) were considered as vitamin
D deficiency. Vitamin D insufficiency was defined as ≥50 and
<75 nmol/L (21–29 ng/mL), whereas vitamin D sufficiency was
defined as ≥75 nmol/L (30 ng/mL) [28, 29].
Statistical analysis
For statistical analysis of the results, a chi-square test with a
0.05 two-sided significance level was used (SPSS 22.0 soft-
ware, IBM Corp, Armonk, NY).
Review
Type of studies and outcome measures
All types of studies comparing vitamin D status and autoanti-
bodies in patients with or without autoimmune diseases were
included in this review. Meta-analysis and systematic review
articles were excluded. Only articles published in English
were used.
A full paper review was performed when abstracts de-
scribed vitamin D levels in relation to the presence of autoan-
tibodies and/or antibody titers. Exclusion of articles was based
on the absence of (statistical) analysis of the (possible) asso-
ciation between serum vitamin D levels and the presence of
autoantibodies and/or antibody titers.
Search methods
A search in MEDLINE, PubMed, and the Cochrane database
from their inception to February 2016 was performed. The
used search terms in the PubMed NLM catalog Medical
Subject Heading database relevant to this review were
“Vitamin D,” “Vitamin D [Mesh],” “Vitamin D deficiency
[Mesh],” “Autoantibodies,” and “Autoantibodies [Mesh].”
Abstracts from 176 search hits were screened for eligibility.
Table 1 Criteria for the diagnosis of ASIA
Major criteria
• Exposure to an external stimulus (infection, vaccine,
silicone, adjuvant) prior to clinical manifestations.
• The appearance of “typical” clinical manifestations:
Myalgia, myositis, or muscle weakness
Arthralgia and/or arthritis
Chronic fatigue, un-refreshing sleep, or sleep disturbances
Neurological manifestations (especially associated with
demyelination)
Cognitive impairment, memory loss
Pyrexia, dry mouth
• Removal of inciting agent induces improvement.
• Typical biopsy of involved organs
Minor criteria:
The appearance of autoantibodies or antibodies directed
at the suspected adjuvant
• Other clinical manifestations (i.e., irritable bowel syndrome)
• Specific HLA (i.e., HLA DRB1, HLA DQB1)
• Evolvement of an autoimmune disease (i.e., multiple sclerosis,
systemic sclerosis)
ASIA autoimmune/inflammatory syndrome induced by adjuvants
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Study selection
Titles and abstracts were screened for eligibility according to the
inclusion criteria by the first author. When included outcome
measures were unclear after regarding the abstract, articles were
retrieved in full text for additional assessment. After screening
the 176 PubMed abstracts according to the inclusion criteria, 38
articles were retrieved for full paper review. Also, a manual
search of the reference lists of the selected articles was per-
formed, which resulted in 19 additional articles for the full paper
review. Only published data were used. A total of 57 articles
were retrieved for detailed full paper review. Criteria for exclu-
sionweremet in 10 articles, leaving 47 articles thatwere included
in the final systematic review. A flow diagram of the selection
process is shown in Fig. 1.
Data extraction
Data relevant to the pre-stated outcome measures, the charac-
teristics of the study, participants, and relevant statistical anal-
ysis of a (possible) association between the outcome measures
were abstracted for this review.
Results
Vitamin Dmeasurements were available for analysis in 131 of
135 patients with ASIA in relation to SIIS (Table 2). Thirty-
three patients (25%) presented with vitamin D deficiency
(<50 nmol/L), 37 (28%) with vitamin D insufficiency (≥50
and <75 nmol/L), and 61 (47%) with vitamin D sufficiency
(≥75 nmol/L). No differences were observed in clinical char-
acteristics between groups.
Twenty-three patients (18%) tested positive for autoanti-
bodies. In these 23 patients, one or more antibodies were
detected (Table 3). Eighteen of these patients (78%) had either
a vitamin D deficiency or insufficiency (median vitamin D
level 60.5 mmol/L), whereas five patients (22%) had suffi-
cient vitamin D levels. The risk to develop autoantibodies
was significantly increased in vitamin D deficient and/or in-
sufficient patients [RR 3.14; 95% CI, 1.24–7.95; p = 0.009].
Review
Forty-seven studies were reviewed (17 case–control studies,
19 cross-sectional studies, 1 cross-sectional case–control
study, 10 cohort studies). The selected articles will be present-
ed according to five subcategories: autoimmune thyroid dis-
eases, connective tissue diseases, inflammatory arthritides,
multiple sclerosis, and other studies.
Autoimmune thyroid diseases
In several epidemiological studies, the association between vita-
min D levels and the presence of autoimmune thyroid diseases
(AITDs) has been investigated [30]. Kivity et al. examined serum
vitamin D levels in relation to anti-thyroid peroxidase (anti-TPO)
and anti-thyroglobulin (anti-TG) antibodies in 92 patients with
thyroid diseases (28 patients with Hashimoto’s thyroiditis, 22
patients with Graves’ disease, 42 patients without evidence for
autoimmunity) and 98 age-matched healthy control subjects
[31]. They documented a significantly higher prevalence of vita-
min D deficiency (<10 ng/mL) in patients with thyroid diseases
(58/92) compared to healthy controls (30/98) (p < 0.001).
Vitamin D deficiency was present particularly in patients with
Fig. 1 Flow diagram of study
enrolment in this review
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Hashimoto’s thyroiditis (22/28; p = 0.001) and in patients with
Graves’ disease (14/22; p = 0.01). As a consequence, vitamin D
deficiency was found to be correlated with the presence of anti-
thyroid antibodies (p = 0.01) [31]. Choi et al. observed in a cross-
sectional study that serum 25(OH)D levels were significantly
lower in anti-TPO-positive (427/2793) compared to anti-TPO-
negative (2366/2793) female euthyroid subjects (p = 0.03) [32].
In a subgroup analysis of pre- (n = 908) and postmenopausal
(n = 1885) women, the serum 25(OH)D levels were significantly
lower in pre-menopausal women with anti-TPO antibodies
(p = 0.049) but not in postmenopausal women with these anti-
bodies (p = 0.186) [32]. Also, Goswami et al. found a significant
inverse correlation between serum vitamin D levels and anti-
TPO positivity (p = 0.04) in an Asian Indian population [33].
Arslan et al. found anti-TPO positivity more frequently observed
in healthy volunteers with severe (<10 ng/mL) and moderate
(10–20 ng/mL) vitamin D levels, compared to those with normal
vitamin D levels (≥20 ng/mL) [34]. Additionally, in antibody-
positive patients, a significant inverse correlation between anti-
TPO and anti-TG titers and 25(OH)D levels (p = 0.017 for anti-
TPO and p = 0.05 for anti-TG) was found [34]. In a case–control
study, Unal et al. found that anti-TG and anti-TPO titers were
significantly higher in vitamin D-deficient AITD patients (183/
281) than in vitamin D-sufficient AITD patients (98/281)
(p = 0.02 and p = 0.003, respectively, for anti-TG and anti-
TPO) [35]. In this study, the 281 AITD patients consist of 254
patients with Hashimoto thyroiditis and 27 patients with Graves’
disease. Several other studies also found a negative correlation
between serum vitamin D levels and anti-thyroid antibody levels
[36–40]. Mazokopakis et al. found that anti-TPO levels were
significantly higher in vitamin D-deficient patients with
Hashimoto’s thyroiditis (HT) (n = 186) compared to HT patients
with no vitamin D deficiency (n = 32) (364 ± 181 vs.
115.8 ± 37.1 IU/mL, p < 0.0001) [36], whereas Bozkurt et al.
found that serum 25(OH)D levels were inversely correlated with
anti-TPO (p < 0.001) and anti-TG levels (p < 0.001) in subjects
with HT [36]. Furthermore, Bozkurt observed that serum
25(OH)D levels in HT patients were significantly lower than in
healthy controls [37]. Shin et al. found that AITD patients (65
Hashimoto’s thyroiditis and 46 Graves’ disease) with anti-
thyroid antibodies had lower levels of serum 25(OH)D than con-
trol patients without positive anti-thyroid antibodies (12.6 ± 5.5
vs. 14.5 ± 7.3 ng/mL, respectively, p < 0.001) [38]. They also
found that 25(OH)D levels were inversely correlated with the
anti-TPO levels (p < 0.001) in the HT and Graves’ patients.
More recently, Wang et al. analyzed a total of 1714 Chinese
healthy adults and reported that subjects that tested positive for
anti-TG (n = 315) had lower serum 25(OH)D levels compared to
subjects who were anti-TG negative (p < 0.01) [39].
Furthermore, they observed that higher anti-TG titers were asso-
ciated with lower 25(OH)D levels independent of age, ethnicity,
Table 2 The presence of clinical manifestations in vitamin D subgroups












Myalgia, myositis, or muscle weakness 18 17 41
Arthralgia and/or arthritis 31 33 58
Fatigue, unrefreshing sleep or sleep disturbances 32 37 60
Neurological manifestationsa 7 7 16
Cognitive impairment, memory loss 25 30 47
Pyrexia 23 22 48
Dry eyes and/or dry mouth (sicca) 27 24 47
aNeurological manifestations: TIA/CVA or demyelination
Table 3 Autoantibodies detected in 23b patients with ASIA in relation
to SIIS











ANA antinuclear antibodies, anti-dsDNA anti-double-stranded DNA an-
tibodies, anti-SSA anti-Sjögren’s syndrome-related antigen A, anti-SSB
anti-Sjögren’s syndrome-related antigen B, anti-CENPB anti-centromere
protein B, anti-Scl-70 anti-topoisomerase I, anti-CL anti-cardiolipin,
ANCA anti-neutrophil cytoplasmic antibodies, IgM-RF IgM rheumatoid
factor, anti-CCP anti-cyclic citrullinated peptide antibody
a ANA specificities: anti-dsDNA (n = 1), anti-SSA (n = 2), anti-SSB
(n = 1), anti-CENP-B (n = 1), anti-Scl70 (n = 1)
b One patient had two autoantibodies (anti-CCP and ANCA)
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and TSH levels in females but not in males (p = 0.014). Finally,
in non-lactating women with postpartum thyroiditis, anti-TPO
and anti-TG titers were found to be inversely correlated with
vitamin D levels (p < 0.001) [40].
In contrast, D’Aurizio et al. did not observe statistically
significant differences in vitamin D levels between healthy
controls and either patients with HT and/or Graves’ disease
(n = 100) and anti-TPO and/or anti-TSH receptor autoanti-
body positivity [41]. Also, Ma et al. did not find serum
25(OH)D levels to be associated with anti-TPO or anti-TG
levels in 70 patients with newly diagnosed HT [42].
However, an association between serum 25(OH)D levels
and anti-TSH receptor autoantibody levels was observed in
their 70 patients (p = 0.036) [42]. Yasuda et al. evaluated 26
female patients with newly onset Graves’ disease and found
no association between serum 25(OH)D levels and anti-TSH
receptor autoantibody levels [43]. In women with polycystic
ovary syndrome and positive anti-TPO and/or anti-TG anti-
body levels, no correlation between 25(OH)D levels and these
antibodies was seen [44]. Finally, Effraimidis et al. reported a
longitudinal study with a 5-year follow-up period in which
serum 25(OH)D levels of 521 euthyroid subjects were ana-
lyzed and related to the occurrence of thyroid peroxidase an-
tibodies (anti-TPO) [45]. Subjects were euthyroid women
who had first- or second-degree relatives with overt AITD
who had normal TSH and no thyroid antibodies at baseline.
Subjects that developed anti-TPO within a period of 5 years
were compared to subjects who remained anti-TPO negative,
matched for age, BMI, smoking status, estrogen use, month of
blood sampling, and duration of follow-up [45]. Sixty-seven
subjects became positive for anti-TPO during follow-up, with-
out developing abnormal TSH. No association with serum
25(OH)D levels was reported.
In conclusion, several studies suggested an association be-
tween the presence of anti-TPO and/or anti-TG and vitamin D
levels and/or between autoantibody level and vitamin D level
(Table 4). In a prospective study, however, vitamin D levels
were not found to be a risk factor for the development of anti-
TPO.
Connective tissue diseases
Low levels of vitamin D are often found in systemic lupus
erythematosus (SLE) patients [46, 47]. Vitamin D levels are
lower in postmenopausal SLE patients (n = 80) compared to
pre-menopausal SLE patients (n = 80) (p = 0.02) [48]. No
association, however, could be observed between vitamin D
food intake and supplements and risk of the development of
SLE [49]. ANA-positive SLE patients are more likely to have
vitamin D deficiency (≤20 ng/mL) compared to ANA-
negative SLE controls (p = 0.011) [46]. Also, anti-dsDNA
autoantibody levels increased from normal vitamin D concen-
trations, to insufficient vitamin D levels and from insufficient
to vitamin D-deficient patient subsets as found in 177
Hungarian SLE patients (p = 0.021) [48]. In women with
newly diagnosed SLE, Bonakdar et al. also found higher titers
of anti-dsDNA antibodies with more severe vitamin D defi-
ciency (p < 0.001) [50]. Also, Mok et al. showed a significant
negative correlation between 25(OH)D levels and anti-
dsDNA levels (p = 0.02) or anti-C1q levels (p = 0.02) in their
SLE patients (n = 290) [51]. In contrast, Thudi et al. found
higher levels of anti-dsDNA in a small group of female lupus
patients with levels of vitamin D that were greater than
47.7 nmol/L compared to subjects with 25(OH)D levels lower
than 47.7 nmol/L (p = 0.0069) (n = 37) [52]. Finally, in a small
study performed in 28 Saudi children with SLE, levels of
25(OH)D tended to be inversely correlated with anti-dsDNA
titers and ANA [53].
Also, in other connective tissue diseases, low levels of vi-
tamin D are found to be correlated with autoantibodies. In
patients with Sjögren’s syndrome, an inverse correlation be-
tween the concentrations of 25(OH)D and the titers of IgM
rheumatoid factor were found (n = 25) [54]. In patients with
mixed connective tissue disease (MCTD), higher serum levels
of anti-U1-RNP (anti-ribonucleoprotein) antibodies were
found in patients with low vitamin D levels (p = 0.022) [55].
Also, in 161 undifferentiated connective tissue disease
(UCTD) patients, autoantibody profiles showed that serum
levels of anti-U1-RNP, anti-SSA, and anti-CCP antibodies
were inversely correlated to vitamin D levels (p < 0.05) [56].
During an average follow-up period of 2.3 years, 35/161 pa-
tients developed an established connective tissue disease.
Vitamin D levels were lower in these patients compared to
the vitamin D levels as found in the 126/161 UCTD patients
that did not develop an established CTD (14.7 ± 6.45 vs.
33.0 ± 13.4 ng/mL, p = 0.0001) [56]. In a cross-sectional study
in 23 pre-menopausal women with primary anti-phospholipid
syndrome (APS), serum vitamin D levels and IgG and IgM
anti-cardiolipin (anti-CL) antibodies were investigated and
compared to vitamin D levels in 23 age- and race-matched
healthy controls [57]. Lower serum levels of 25(OH)D
[21.64 mg/dL (11.26) vs. 28.59 mg/dL (10.67), p = 0.039]
were found in the APS patients when compared to controls.
No correlation, however, was found between vitamin D levels
and IgG anti-CL levels (p = 0.222) and/or IgM anti-CL levels
(p = 0.535). In a large multinational study in patients with
systemic sclerosis (SSc), vitamin D concentrations and the
presence of anti-nuclear antibodies (ANA), anti-SCL70 anti-
bodies, and RF were determined [58]. Three hundred twenty-
seven serum samples of European patients with SSc and 141
samples of healthy controls were studied. Patients with SSc
had significantly lower serum vitamin D concentrations com-
pared to healthy controls (p < 0.001). An inverse relation
between RF positivity and the vitamin D concentration was
found (p < 0.001). No association was found between vitamin
D levels and the presence of ANA and/or anti-SCL70.
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In conclusion, an inverse correlation between vitamin D
levels and the presence of autoantibodies in connective tissue
diseases has been described (Table 5). In several studies, vita-
min D deficiency was found to be inversely correlated with
autoantibody titers in connective tissue diseases, although
findings are at present not conclusive.
Inflammatory arthritides
In the Women’s Iowa Health Study, i.e., a prospective cohort
of 29,368 women, it was demonstrated that vitamin D food
intake was inversely associated with the risk to develop rheu-
matoid arthritis (RA) (n = 152) [59]. However, in smaller
Table 4 Studies in which vitamin D levels are correlated to thyroid autoantibodies in thyroid autoimmune diseases (AITDs)
Author Year Country Subjects Vitamin D (ng/ml) Thyroid
autoantibodies
P value* Reference
Kivity S. et al. 2011 Hungary 92 thyroid diseasesa (28 HT, 22




Choi Y.M. et al. 2014 Korea 427 TPOAb +,
2366 TPOAb – (CTRL)
22.0 ± 0.6 vs.
23.5 ± 0.3
anti-TPO 0.03 [32]
Goswami et al. 2009 India 642 (559 vit. D ≤ 25 nmol/l,
83 vit. D > 25.0 nmol/l)
14.5 ± 3.5 vs.
37.5 ± 16.3
anti-TPO 0.04† [33]
Arslan M.S. et al. 2015 Turkey 155 volunteers (53 group 1f, 61
group 2g, 41 group 3h)
<10 vs.






Unal A.D. et al. 2014 Turkey 281 AITDs (254 HT, 27 GD),
124 CTRLd







Mazokopakis et al. 2015 Greece 218 HT (186 vit. D deficiency,
32 vit. D sufficiency)





Bozkurt N. et al. 2013 Turkey 360 AITDs (180 HT, 180 HTi),
180 CTRL
11.4 ± 5.2 vs.







Shin D.Y. et al. 2014 Korea 111 AITDs,
193 non-AITDs
12.6 ± 5.5 vs.
14.5 ± 7.3
anti-TPO <0.001 [38]







Krysiak R. et al. 2016 Poland 38 PPTk,
21 CTRLl


























Muscogiuri G. et al. 2015 Italy 50 PCOS (12 TPOAb/TGAb +),
38 TPOAb/TGAb -)





Effraimidis G. et al. 2012 Netherlands 67 AITDsb,
67 CTRLc
21.6 ± 9.2 vs.
21.2 ± 9.3
anti-TPO NS [45]
AITDs = Autoimmune Thyroid Diseases; HT = Hashimoto's thyroiditis; GD = Graves' disease; CTRL = Controls; NR = Not reported; anti-TPO =
Antithyroid peroxidase; anti-TG = anti-thyroglobulin antibodies; PCOS = Polycystic Ovary Syndrome.
* Correlation between vitamin D levels and positive thyroid antibodies
†Controlled for age
a 58 vitamin D deficiency (<10 ng/ml), 34 vitamin D >10 ng/ml
b anti-TPO negative at baseline (cases)
c anti-TPO negative (controls)
d age matched healthy controls
e matched for sex, age, and smoking status with the GD patients
f Vitamin D level < 10 ng/ml
gVitamin D level 10–19.9 ng/ml
hVitamin D level ≥ 20 ng/ml
i sex-, age-, and body mass index (BMI)-matched euthyroid subjects with newly diagnosed HT
j healthy female subjects
k non-lacting L-thyroxine-treated women with postpartum thyroiditis (PPT)
l matched healthy postpartum women
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studies, no association was found. Firstly, in 722 patients with
RA from the Nurses’ Health Study and Nurses’ Health Study
II [49], and secondly, in the study by Nielen et al. (n = 79), no
association between vitamin D deficiency and later develop-
ment of RAwas observed [60]. Feser et al. found in a healthy
population at increased risk for RA that 25(OH)D levels were
not associated with the presence of RA-related autoantibodies
(76 subjects being positive for anti-CCP and/or RF) (P = 0.15)
[61]. In contrast, RA patients with severe vitamin D deficien-
cy (serum levels ≤15 nmol/L) (n = 15) were shown to test
more frequently positive for RF (100%) when compared to
RA patients with normal vitamin D serum levels (n = 200)
(77.5%) (p = 0.05) [62]. In a 10-year prospective cohort study
of 775 RA, 738 ankylosing spondylitis (SPA), and 721 psori-
atic arthritis (PsA) patients, 25(OH)D levels, RF, and anti-
cyclic citrullinated peptide (anti-CCP) antibodies were mea-
sured [63]. Levels were compared to 677 subjects without
inflammatory rheumatic diseases. Five hundred twenty-eight
RA patients (68.1%) were found to be RF positive and 482
RA patients (62.2%) anti-CCP positive. The prevalence of anti-
CCP positivity was significantly higher in the 25(OH)D defi-
ciency group (<20 ng/mL) (p < 0.022) compared to patients
with sufficient levels of vitamin D [63]. Subclinical gut inflam-
mationmay be present in patients with SPA. In a cross-sectional
study by Teichman et al., 47/76 patients with SPA tested posi-
tive for human anti-tissue-transglutaminase-IgA (htTG)
Table 5 Studies in which vitamin D levels are correlated to CTD autoantibodies in connective tissue diseases (CTDs)















Costenbader K.H. et al. 2008 Boston,
USA
190 SLE NR Risk of SLE NS [49]









Thudi A. et al. 2008 Texas, USA 37 SLE >47 nmol/l vs.
<47 nmol/l
anti-dsDNA 0.0069 [52]
AlSaleem A. et al. 2015 Saudi Arabia 28 SLE children (26
female, 2 male)










Hajas A. et al. 2015 Hungary 125 MCTD,
48 CTRLd














Paupitz J.A. et al. 2010 Brazil 23 APSe,
23 CTRLf
21.64 ± 11.26 vs.


















SLE = Systemic lupus erythematosus; ANA = Antinuclear antibodies; anti-dsDNA = Anti-double stranded DNA antibodies; APS = Antiphospholipid
syndrome; PV = Pemphigus vulgaris; IgM RF = IgM rheumatoid factor; IgA RF = IgA rheumatoid factor; anti-CL IgA = anti-cardiolipin IgA; RNP =
ribonucleoprotein; anti-SSA = anti-Sjögren's-syndrome-related antigen A; anti-CCP = Anti-cyclic citrullinated peptide antibody; SSc = Systemic
sclerosis; anti-SCL70 = anti-topoisomerase I; RF = Rheumatoid factor
a Healthy matched controls; n=14 ANA-positive^ , n=18 ANA-negative^^
b 5 mild vitamin D deficiency, 25 moderate vitamin D deficiency, 7 severe vitamin D deficiency
c 277 vitamin D insufficiency (<30 ng/ml), 77 vitamin D deficiency (<10 ng/ml)
d age- and sex-matched healthy controls
e pre-menopausal women
f age- and race-matched healthy controls
g healthy controls
h Correlation between vitamin D levels and positive CTD antibodies
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antibodies. These patients had significant lower 25(OH)D
levels compared to SPA patients that tested negative for anti-
htTG antibodies (mean 17.4 vs. mean 41.5 ng/mL; p < 0.005)
[64].
In conclusion, the relation between vitamin D food
intake and the risk of development of RA later in life is
controversial. Furthermore, some studies suggest that
there is an inverse correlation between vitamin D levels
and the presence of RA-related autoantibodies (RF and/or
anti-CCP) in patients with RA (Table 6) and/or anti-TTG
antibodies in SPA.
Multiple sclerosis
Low levels of vitamin D are common in patients with
multiple sclerosis (MS) and are associated with more se-
vere disability and an increased risk for relapses of the
disease [65]. Also, the geographical distribution of MS
suggests that people living in areas were vitamin D levels
are low are more prone to develop MS. Furthermore, vi-
tamin D supplementation may correct immunological ab-
normalities that are observed in MS [66, 67]. As a conse-
quence, vitamin D supplementation is currently being
studied for the prevention of disease relapses [68]. An
association between low vitamin D levels and MS-
related antibodies are, however, rarely reported. In a
cross-sectional study of pediatric-onset MS, vitamin D
status was found to be related to antibody levels to
cytomegalovirus (CMV), while antibodies to other viruses
(Epstein–Barr virus, herpes simplex virus 1 or 2) were not
found to be associated with vitamin D levels [69].
Epstein–Barr virus (EBV) is postulated to play an impor-
tant role in the pathogenesis of MS by infecting B cells
[70]. Importantly, antibodies against the EBV antigens are
associated with an increased risk of developing MS later
in life [71]. Salzer et al. showed an inverse association
between vitamin D levels and antibody titers against
EBV in MS patients [72]. Décard et al. investigated serum
25(OH)D levels and EBV immunoreactivity in 25 individ-
uals who donated blood prior to the first clinical MS
manifestation [73]. Cross-sectional analyses revealed a
gradual decrease of vitamin D levels and increase of
anti-EBNA-1 IgG titers before the first clinical manifesta-
tion of MS. Furthermore, Disanto et al. showed decreased
anti-EBNA-1 IgG levels after 12 weeks of vitamin D sup-
plementation in 15 relapsing–remitting MS (RRMS) pa-
tients (p = 0.016) [74]. Another study by Najafipoor et al.
examined the effect of vitamin D supplementation for
6 months on the anti-VCA IgG and anti-EBNA-1 IgG
levels in 40 RRMS patients [75]. They found six patients
(15%) with a decline in the level of anti-VCA titers and
six patients (15%) with a reduction in anti-EBNA1 titers
in the supplemented group. There was, however, no sig-
nificant relationship between the vitamin D levels and
antibody levels (VCA IgG p = 0.420; EBNA1 IgG
p = 0.853).
Table 6 Studies in which vitamin D levels are correlated to autoantibodies associated with inflammatory arthritides
Author Year Country Subjects Vitamin D
(ng/ml)
Vitamin D effect /
Autoantibodies
P valued Reference
Merlino L.A. et al. 2004 USA 152 RA +, 29.368
RA -
NR Risk of RA
(RR 0.67)
0.05 [59]
Nielen N.M. et al. 2006 The Netherlands 79 RA,
79 CTRLa
<20 nmol/l Risk of RA NS [60]
Costenbader K.H. et al. 2008 Boston, USA 722 RA NR Risk of RA NS [49]
Feser M. et al. 2009 USA 79 RA,
154 CTRLb





Haga H.J. et al. 2013 Denmark 302 RA ≤15 nmol/l RF 0.05† [62]
Urruticoechea-Arana et al. 2015 Spain 775 RA, 738 SPA





Teichman J. et al. 2010 Germany 76 SPA,
116 PsA
17.4 ± 13.19 vs.
41.5 ± 44.21
htTG <0.005 [64]
NR = not relevant; RR = Relative Risk; NR = Not reported; RA = Rheumatoid Arthritis; SLE = Systemic lupus erythematosus, anti-CCP = Anti-cyclic
citrullinated peptide antibody; SPA = Ankylosing Spondylitis
a healthy blood donors matched for age, sex, and time of donation
b autoantibody-negative controls
c non-CIRD (chronic inflammatory rheumatic diseases) subjects
d Correlation between vitamin D levels and positive inflammatory arthritides antibodies
e compared vitamin D ≤15 nmol/l (n=15) to normal vitamin D levels (n=200)
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In summary, both vitamin D levels and autoantibodies
against EBV are reported to be important in the pathogenesis
of MS. A causal relation between these two etiological factors
is suggested in several studies (Table 7).
Other studies
Inflammatory bowel disease (IBD) is another disease that is
linked to low vitamin D levels [17, 76]. A prospective study
by Santos-Antunes et al. found an inverse relationship be-
tween vitamin D levels and ANA positivity in IBD patients
[77]. The presence of ANA has also been shown to correlate
with low serum vitamin D levels in patients with leprosy
(p < 0.001) [78]. Ritterhouse et al. observed that ANA-
positive healthy controls are significantly more likely to be
deficient in vitamin D levels than ANA-negative healthy con-
trols (p = 0.011) [46]. Nuti et al. found that 24 women with
osteoporosis in the presence of coeliac disease and high levels
of serum IgG anti-gliadin antibodies (IgG AGA) and tissue
transglutaminase antibodies (anti-TTG) had lower serum
25(OH)D levels compared to 231 women with primary oste-
oporosis without coeliac disease (p < 0.01) [79]. They also
found an inverse correlation between the serum 25(OH)D
levels and the serum anti-TTG titers in these 24 women with
primary osteoporosis and coeliac disease (p < 0.001). Karakan
et al. investigated the presence of serum IgA anti-endomysial
(IgA EMA) antibodies in relation to serum 25(OH)D levels in
135 patients with idiopathic osteoporosis and found that 13
patients (9.6%) which tested positive for IgA EMA had lower
serum 25(OH)D levels compared to IgA EMA-negative pa-
tients (p < 0.01) [80]. However, none of these 13 patients had
findings consistent with coeliac disease. Furthermore, in a
cross-sectional study by Ota et al. of 133 women with recur-
rent pregnancy losses, a significantly higher prevalence of
anti-phospholipid antibodies and TPO antibodies was found
in 63 patients with low vitamin D levels (<30 ng/mL) com-
pared to 70 patients with normal vitamin D levels (p < 0.05
each) [81]. A prospective study by Njemini et al. investigated
the prevalence of several organ-specific and non-organ-
specific autoantibodies and serum 25(OH)D levels in 152 un-
selected Cameroonians [82]. No association between the pres-
ence of autoantibodies and serum 25(OH)D levels could be
found in this African population. Finally, Carvalho et al. ob-
served anti-vitamin D antibodies in a subset of patients with
several different autoimmune diseases [83], but could not find
a significant difference in serum 25(OH)D levels between the
anti-vitamin D antibody-positive (n = 7) and anti-vitamin D-
negative (n = 164) patients.
In conclusion, an inverse correlation between serum vita-
min D levels and the presence of autoantibodies in several
other conditions has been suggested as well (Table 8).
Discussion
The aim of our study was to investigate the relation between
vitamin D levels in patients with ASIA in relation to silicone
implant incompatibility and the presence of autoantibodies.
Vitamin D deficiency or insufficiency was found to be related
to the presence of autoantibodies in our patients with silicone
breast implants. A critical limitation to this finding is that we
did not perform a study in control patients. Whether vitamin D
deficiency is also related to the presence of autoantibodies in
healthy control women remains therefore unknown.
Table 7 Studies in which vitamin D levels are correlated to autoantibodies associated with Multiple sclerosis (MS)
Author Year Country Subjects Vitamin D
(ng/ml)
Vitamin D effect /
Autoantibodies
P valued Reference







Salzer J. et al. 2013 Sweden 192 MS,
384 CTRL
NR anti-EBNA1 0.03 [72]
Décard B.F.et al. 2012 Germany 25 pre-CIS,
25 CTRLb
NR anti-EBNA1 <0.01 [73]
Disanto G. et al. 2013 The Netherlands 15 RRMSc NR anti-EBNA1 0.016 [74]







NR = Not reported; CIS = clinically isolated syndrome (prior to first clinical MS manifestation); CMV = cytomegalovirus; EMB = Epstein Barr Virus;
HSV =
Herpes Simplex Virus; EBNA = Epstein-Barr Nuclear Antigen; RRMS = Relapsing remitting MS
a Pediatric-onset MS
b age- and gender-matched healthy blood donors
c vitamin D supplementation (n=27) and age- and gender-matched healthy blood donors
d Correlation between vitamin D levels and positive antibodies
Clin Rheumatol
Furthermore, we reviewed the literature regarding an associa-
tion between vitamin D deficiency and the development of
autoantibodies in several other (autoimmune) diseases. To
our knowledge, this link has not been reviewed before.
Conflicting data regarding the relation between vitamin D
levels and autoantibodies were found since low vitamin D
levels were linked to the presence of autoantibodies and/or
the antibody titers in some, but not all studies. Thirty-one
studies described a significant negative correlation between
serum vitamin D levels and autoantibodies: ten for anti-
thyroid antibody levels [31–40], nine for autoantibodies in
connective tissue diseases [46, 48, 50–52, 54–56, 58], two
for RA-related autoantibodies (RF and/or anti-CCP) [62,
63], one for anti-TTG antibodies [64], four for autoantibodies
against EBV in MS patients [69, 72–74], and five for autoan-
tibodies in several other (autoimmune) diseases [77–81].
Thirteen studies could, however, not confirm this correlation
[41–45, 49, 53, 57, 60–61, 75, 82–83].
Vitamin D deficiency has been underestimated for many
years as a health problem. Importantly, the role of vitamin D
insufficiency and/or deficiency in the development of different
autoimmune diseases is at present increasingly studied [47, 84].
It has been demonstrated that many cells of the immune system
express vitamin D receptors (VDRs), e.g., monocytes and den-
dritic cells (DC) [18]. Whereas resting T and B cells express
negligible VDR, activation of these cells results in upregulation
of VDR expression [19]. Furthermore, activated B cells express
CYP27B1 and CYP24A1 enzymes, which are responsible for
the synthesis and breakdown of the active metabolite of vitamin
D, thereby regulating vitamin D activity in the microenviron-
ment [19, 68, 85]. Importantly, Chen et al. demonstrated that
1,25(OH)2D has potent direct effects on B cell responses,
inhibiting proliferation, generation of class-switched memory
B cells, plasma cell differentiation, and Ig production [19].
Furthermore, they demonstrated that 1,25(OH)2D induced in-
creased apoptosis of proliferating B cells [19]. Chen et al. there-
fore suggested that vitamin D deficiency could contribute to B
cell hyperactivity, breakdown of B cell tolerance, and produc-
tion of autoantibodies in SLE patients [19]. Subsequently, it
was demonstrated in in vitro experiments that synthesis of
IgM, IgG, and IgA by various stimuli was inhibited in the
presence of 1,25(OH)2D [19]. These in vitro inhibitory effects
of vitamin D are, however, not confirmed in vivo [86–88].
Ritterhouse et al. found that SLE patients with more pro-
nounced B cell activation had lower mean 25(OH)D levels
compared to SLE patients with less B cell activation [46].
Importantly, they also found that patients with vitamin D defi-
ciency had highermean serum IFNα activity than patients with-
out a vitamin D deficiency [46]. IFNα is produced in large
amounts by activated dendritic cells (DCs) and has multiple
pro-inflammatory effects on autoreactive cells and is therefore
considered to be a central player in the progression to and
maintenance of autoimmunity [89]. Excessive dendritic cell
activity could therefore be another hypothesis for the
Table 8 Studies in which vitamin D levels are correlated to antibodies in other autoimmune diseases





Santos-Antunos J. et al. 2016 USA 68 IBD (56 CD, 12 UC) <4 ng/ml ANA <0.05 [77]
Ribeiro S.L.E. et al. 2012 Brazil 87 Leprosy (22 ANA +,
55 ANA -)
31.20 ± 10.8 vs.
53.03 ± 24.99
ANA <0.001 [78]
Nuti R. et al. 2001 Italy 53a IgG AGA + (24
TG-Ab +, 29 TG-Ab -)
17.8 ± 7.2 vs.




Karakan T. et al. 2007 Turkey 135 low BMDb (13
EMA +, 122 EMA -) 11.6 ± 1.89 vs.
IgA EMA <0.01 [80]
Ota K. et al. 2014 USA 133 RPL (63 vit D. def.,






Njemini R. et al. 2002 Belgium 152 Cameroonians ≥30 ng/ml
12.5 ± 3.2 vs.
Various AAbe NS [82]
Carvalho J.F. et al. 2007 Israel 171 SLE, 56 APS, 18
PV, 94 CTRLf
21.1 ± 7.7 mg/l
28.4 ± 9.6 vs.
26.4 ± 13.9
anti-vitamin D Ab, NS [83]
IBD = Inflammamtory Bowel Disease; CD = Crohn’s disease; UC = Ulcerative colitis; BMD = Bonemineral density; IgA EMA = IgA anti-endomysial;
RPL = Recurrent pregnancy losses; APS = Antiphospholipid syndrome; APA = Antiphospholipid antibody
a Postmenopausal osteoporotic women
b Idiopatic
c Any IgG or IgM antibodies to phospholipids
d Correlation between vitamin D levels and positive antibodies
e Organ-specific and non-organ-specific autoantibodies
f Comparing n=7 anti-vitamin D positive and n=164 anti-vitamin D negative
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production of autoantibodies in vitamin D-deficient patients.
Whether these pathophysiological hypotheses are relevant for
the development of autoimmune diseases is, however, at pres-
ent not clear.
Conclusion
Vitamin D may act as a regulatory agent of the immune sys-
tem. Vitamin D deficiency is found to be related to the pres-
ence of autoantibodies in patients with silicone implant in-
compatibility syndrome. In line with our study, we found sev-
eral reports that suggested that there is evidence that vitamin D
levels are related to the presence and/or levels of autoanti-
bodies in thyroid autoimmune diseases (AITDs), connective
tissue diseases (CTDs), multiple sclerosis (MS), and several
other (autoimmune) diseases. Randomized, controlled trials
must be performed to elucidate whether vitamin D supple-
mentation is beneficial as preventive therapy in patients with
silicone breast implants to inhibit the development of
autoantibodies.
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